15.6 C
London
Wednesday, June 11, 2025
Subscribe
Home Tags Eisai

Tag: Eisai

Japan – Eisai to Launch “Pariet S,” the First Proton Pump...

Correspondent - 0

Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro

Editor - 0

Japan – Eisai Representative Corporate Officer and CEO Haruo Naito Awarded...

Leslie Atkins - 0

Japan – Eisai Selected as a Nadeshiko Brand 2025 as a...

Leslie Atkins - 0

Japan – Eisai: Update on the Co-Promotion of the Oral Antifungal...

Editor - 0

Japan – Eisai Receives Regulatory Review Outcome for Lecanemab as a...

Leslie Atkins - 0

Eisai Enters into License Agreement for the Development and Distribution of...

Editor - 0

Japan – Eisai to Provide Guidance on Reducing the Risk of...

Editor - 0

Japan – Eisai Listed as a Global 100 Most Sustainable Corporation...

Leslie Atkins - 0

Japan – Eisai Receives Positive Opinion from the CHMP in the...

Correspondent - 0

Japan – Eisai Completes Rolling Submission to US FDA for LEQEMBI(R)...

Editor - 0

Japan – Eisai Commences Business Activities At New Pharma Sales Subsidiary...

Correspondent - 0

Japan – Eisai Announces Status Relating to Acquisition of Own Shares

Editor - 0

Japan – Eisai Named to List of The Time 100 Most...

0

Japan – Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug...

0

Japan – Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024

0

Japan – Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched...

0

Japan – Eisai: Research on Treatments for Alzheimer’s Disease Based on...

0

Japan – Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License...

Editor - 0

Japan – Eisai to Divest Rights for Merislon and Myonal in...

0

Japan – Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant...

0

Japan – Eisai Selected as a Nadeshiko Brand 2024 as a...

0

Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan

0

Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South...

0

Japan – Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation...

0

Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan

0

Eisai: “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in...

0

Japan – Eisai Listed as a Global 100 Most Sustainable Corporation...

Editor - 0

Japan – Eisai: The Scientific Advisory Group (SAG) to Convene to...

0

Japan – Eisai Submits Marketing Authorization Application in Japan for Anticancer...

0

Japan – Eisai and Mizuho Sign Sustainability-Linked Loan Agreement

0

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update...

0

Eisai Launches New “Innovation” Page on Corporate Website

0

Japan – Eisai to Present Research from Oncology Portfolio and Pipeline...

0

Japan – Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of...

Editor - 0

Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer’s Day,...

0

Japan – Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for...

0

Japan – Eisai Files Marketing Authorization Application for Lecanemab as Treatment...

0

Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early...

0

Japan – Eisai Enters Into Joint Development Agreement with Blissbio for...

0

Eisai Completes a Major Renovation of Tsukuba Research Laboratories

0

Japan – Eisai Publishes Long-Term Health Outcomes Using Simulation Model of...

0

Japan – Eisai Enters Into Agreement With National Cancer Center to...

0

Japan – Eisai: Additional Detailed Analyses from Phase 2 Study 201...

0

Eisai to Present Research from Oncology Portfolio at The Society of...

0

Japan – Eisai Receives the “Basic Achievement Grand Prize” at the...

0

Eisai Certified as a 2023 Health and Productivity Management Outstanding

Editor - 0

Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s...

Editor - 0

Japan – Eisai Commences Business Activities at New Pharma Sales Subsidiary...

0

Japan – Eisai Listed as a Global 100 Most Sustainable Corporation...

0

Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for...

0

Japan – Eisai Launches Renewed Sustainability Page

0

Japan – Eisai Submits Marketing Authorization Application for Lecanemab as Treatment...

0

Japan – Eisai Submits Supplemental Biologics License Application to FDA for...

Editor - 0

Japan – Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate...

Editor - 0

Japan – Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel)...

Editor - 0

Japan – Eisai and Washington University School of Medicine in St....

0

Japan – Eisai to Present Preclinical and Clinical Research on Eribulin...

0

Japan – Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo,...

0

Japan – Eisai Announces Plans to Submit Application for Partial Change...

0

Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon

0

Japan – Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan...

0

Japan – Eisai and Merck & Co., Inc. Present Results from...

0

Japan – Eisai Presents Results of Post Hoc Analysis of Eribulin...

0

Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series

0

Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022

0

Japan – Eisai Signs the Public-Private Partnership “Kigali Declaration” for Eliminating...

0

Japan – Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab...

0

Japan – Eisai Contributes to the Science of Cancer Medicine at...

0

Japan – Eisai: MHLW Grants Orphan Drug Designation in Japan to...

0

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License...

0

Eisai Initiates Preparation for New Drug Application, Based on the Results...

0

Japan – Eisai: Economic Arrangements of Amendment to Alzheimer’s Disease Treatment...

0

Japan – Biogen and Eisai Amend Collaboration Agreements on Alzheimer’s Disease...

0

Japan – Eisai Certified as the 2022 Health and Productivity Management...

0

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation...

0

Japan – Eisai Receives the Tokyo Governor Prize for Corporate Governance...

0

Japan – Eisai: Update on the Phase 4 ENVISION Confirmatory Study...

0

Japan – Eisai Announces Results and Continued Support of Initiatives for...

0

Japan – Eisai Listed as a Global 100 Most Sustainable Corporation...

0

Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA...

0

Japan – Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning...

0

Japan – Eisai Enters into Commercialization and Distribution Agreement with Gilead...

0

Japan – Eisai to Present Abstracts on Oncology Products And Pipeline...

0

Japan – Eisai and FCNT Enter Into Business Alliance Aiming to...

0

Japan – Eisai Receives the ‘Most Liked!’ IR Award at The...

0

Japan – Eisai: New Phase 3 Data Show Positive Correlation Between...

0

Japan – Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results...

0

Japan – Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in...

0

Japan – Eisai Presents New Data on the Relationship Between Clinical,...

0

Japan – Eisai Initiates Rolling Submission to the U.S. FDA for...

0

Japan – Eisai to Join The Global Environmental Initiative “RE100”

0

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO...

0

Japan – Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the...

0

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of...

0

Japan – Eisai Listed for 20th Consecutive Year in FTSE4Good Index...

0

Japan – Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at...

0

Japan – Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In...

0

Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation...

0

Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s...

0
12Page 1 of 2

Company

Each template in our ever growing studio library can be added and moved around within any page effortlessly with one click.

Latest

Bajaj Markets Empowers Users to Check Their CIBIL Score Within Minutes

Business 0
Pune, June 11 -- Checking the CIBIL score online...

Sundried, Supercharged & Seriously Tasty That’s Hale & Hearty Ragi Noodles !

Business 0
India, June 10 -- In a world craving both...

Two Students of Ashoka University Awarded Prestigious Inlaks Scholarships for 2025

Education 0
Ashoka University is proud to announce that two...

Popular

Bajaj Markets Empowers Users to Check Their CIBIL Score Within Minutes

Business 0
Pune, June 11 -- Checking the CIBIL score online...

Sundried, Supercharged & Seriously Tasty That’s Hale & Hearty Ragi Noodles !

Business 0
India, June 10 -- In a world craving both...

Two Students of Ashoka University Awarded Prestigious Inlaks Scholarships for 2025

Education 0
Ashoka University is proud to announce that two...

Sitemap

© 2022 tagDiv. All Rights Reserved. Made with Newspaper Theme.

Get $10 by answering a Simple Survey. Click Here